Clinical Pharmacology in Transgender Medicine: What Gaps Remain?
Clinical Pharmacology & Therapeutics · 02.11.2026
DOI: 10.1002/cpt.70549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 02.11.2026. Verfasst von Lauren R Cirrincione. Beteiligte Einrichtung: Department of Pharmacy, University of Washington, Seattle, Washington, USA. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Mechanistic information is limited about the effects of gender‐affirming hormone therapy and the unique factors that influence the absorption, distribution, metabolism, and excretion properties of medications across therapeutic classes for transgender people. Opportunities exist to address knowledge gaps in transgender medicine using well‐designed probe substrate studies, endogenous biomarkers of drug‐metabolizing enzymes and transporters, and real‐world data to identify and address factors that contribute to interindividual variability in drug disposition for transgender people across the life course.
Autor:innen und Institutionen
- Department of Pharmacy, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Lauren R Cirrincione
Förderung
- NIGMS NIH HHS
Zitieren
APA
Cirrincione, L. R. (2026). Clinical Pharmacology in Transgender Medicine: What Gaps Remain?. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70549
Vancouver
Cirrincione LR. Clinical Pharmacology in Transgender Medicine: What Gaps Remain?. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70549
BibTeX
@article{Cirrincione2026,
author = {Cirrincione, Lauren R},
title = {Clinical Pharmacology in Transgender Medicine: What Gaps Remain?},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70549}
}
EUVIMED